Research, evidence and implementation learning
Evidence that informs policy, strengthens programmes and improves maternal and newborn health.
Explore MIRNA research
7 publications
Vaccinating women across the life course: Gendered social norms, obligations and vaccine uptake
Two papers in this issue support healthcare providers in vacci-nating women across their life courses. In the first paper, Divakaret al.3 present a synthesis of the global evidence- based recommen-dations for vaccination of women of four key age groups: adoles-cence, reproductive age and pre-conception, during pregnancy andthe postpartum period, and post-menopause. In the second paper,Hodge […]
Vaccination in Pregnancy: An Update for a Changing Time
Introduction Vaccinations in pregnancy have been proven to reduce maternal, fetal, and neonatal morbidity and mortality from infectious diseases.1, 2 It is estimated that 154 million deaths worldwide have been avoided since the introduction of routine vaccinations. Despite the wealth of research and literature to support the safety and efficacy of vaccines in pregnancy, immunization […]
From Evidence to Delivery: Building Readiness for Maternal Respiratory Syncytial Virus Vaccination in Bangladesh
1 Evidence From Global and National Sources Respiratory syncytial virus (RSV) is often regarded as a mild respiratory infection in older children and adults, a perception that does not reflect the high risk it carries for young infants. RSV is a leading cause of acute lower respiratory tract infection, bronchiolitis, and pneumonia in children under […]
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine
Objective To describe preterm birth frequency and newborn and infant outcomes overall and among preterm children in the MATISSE (Maternal Immunization Study for Safety and Efficacy) trial of maternal vaccination with bivalent respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVpreF) to protect infants against severe RSV-associated illness. Methods MATISSE was a global, phase 3, […]
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
Objectives To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF). Methods MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants […]
RSV Prefusion F Protein-Based Maternal Vaccine – Preterm Birth and Other Outcomes
Background Vaccination against respiratory syncytial virus (RSV) during pregnancy may protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F protein-based maternal vaccine (RSVPreF3-Mat) are needed. Methods We conducted a phase 3 trial involving pregnant women 18 to 49 years of age to assess the efficacy and safety of RSVPreF3-Mat. […]
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
Background Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is uncertain. Methods In this phase 3, double-blind trial conducted in 18 countries, we randomly assigned, in a 1:1 ratio, pregnant women at 24 through 36 weeks’ gestation to receive a single intramuscular […]